Publications

Atebimetinib (IMM-1-104) + Modified Gemcitabine/Nab-Paclitaxel (mGnP) Shows Extraordinary Overall Survival (OS) and Favorable Tolerability in First-Line (1L) Metastatic PDAC: Updated Phase 2 Results

MENU
immuneering-logo-no-shadow
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.